TICKERNOMICS Sign up
Last Update: 2023-12-23 05:58:46
ImmunoGen Inc. ( IMGN ) https://www.immunogen.com
29.70USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
IMGN
537.34%
SPY
30.72%
IMGN
326.72%
SPY
112.82%
IMGN
646.23%
SPY
201.04%
IMGN
100.54%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
7393.62
6860.20
5.49
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-101.18
25.71
13.17
-5.16
0.00
-90.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
22.88
98.10
-26.47
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.0764
2.01
1.64
1.26
Other Earnings and Cash Flow Stats:
ImmunoGen Inc. ( IMGN ) Net Income TTM ($MM) is -146.91
ImmunoGen Inc. ( IMGN ) Operating Income TTM ($MM) is -153.43
ImmunoGen Inc. ( IMGN ) Owners' Earnings Annual ($MM) is 0.00
ImmunoGen Inc. ( IMGN ) Current Price to Owners' Earnings ratio is 0.00
ImmunoGen Inc. ( IMGN ) EBITDA TTM ($MM) is -150.38
ImmunoGen Inc. ( IMGN ) EBITDA Margin is -26.47%
Capital Allocation:
ImmunoGen Inc. ( IMGN ) has paid 0.00 dividends per share and bought back 4.567574 million shares in the past 12 months
ImmunoGen Inc. ( IMGN ) has increased its debt by 55.915 million USD in the last 12 months
Capital Structure:
ImmunoGen Inc. ( IMGN ) Interest-bearing Debt ($MM) as of last quarter is 72
ImmunoGen Inc. ( IMGN ) Annual Working Capital Investments ($MM) are -315
ImmunoGen Inc. ( IMGN ) Book Value ($MM) as of last quarter is 561
ImmunoGen Inc. ( IMGN ) Debt/Capital as of last quarter is 12%
Other Balance Sheet Stats:
ImmunoGen Inc. ( IMGN ) has 605 million in cash on hand as of last quarter
ImmunoGen Inc. ( IMGN ) has 134 million of liabilities due within 12 months, and long term debt 72 as of last quarter
ImmunoGen Inc. ( IMGN ) has 248 common shares outstanding as of last quarter
ImmunoGen Inc. ( IMGN ) has 0 million USD of preferred stock value
Academic Scores:
ImmunoGen Inc. ( IMGN ) Altman Z-Score is 15.03 as of last quarter
ImmunoGen Inc. ( IMGN ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
ImmunoGen Inc. ( IMGN ) largest shareholder is Geode Capital Management, LLC owning 4899975 shares at 145.53 ($MM) value
Kristine Peterson(an insider) Sold 20000 shares of ImmunoGen Inc. ( IMGN ) for the amount of $578000.00 on 2023-11-30
0.30% of ImmunoGen Inc. ( IMGN ) is held by insiders, and 84.66% is held by institutions
ImmunoGen Inc. ( IMGN ) went public on 1989-11-16
Other ImmunoGen Inc. ( IMGN ) financial metrics:
FCF:-256.28
Unlevered Free Cash Flow:0.00
EPS:0.49
Operating Margin:22.88
Gross Profit Margin:98.10
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:21.90
Beta:1.26
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ImmunoGen Inc. ( IMGN ) :
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.